DEFM14A: Iris Acquisition Corp. Seeks Stockholder Approval for Liminatus Pharma Merger

Iris Acquisition Corp. is asking its stockholders to approve a business combination with Liminatus Pharma, a clinical-stage biopharmaceutical company.

Summary

• Iris Acquisition Corp. (IRAA) is seeking stockholder approval for a business combination with Liminatus Pharma, LLC.
• The proposed transaction involves Liminatus Merger Sub merging into Liminatus, and SPAC Merger Sub merging into Iris, with Iris surviving as a subsidiary of ParentCo.
• The aggregate consideration for the transaction is 25.0 million shares of ParentCo common stock, valued at $10.00 per share.
• Stockholders will vote on proposals including the business combination, issuance of ParentCo stock, an incentive plan, and charter amendments.
• The Special Meeting of stockholders will be held virtually on August 29, 2024.
• Liminatus Members will own approximately 70.6% of the combined voting power of ParentCo Common Stock, assuming no redemptions.
• The Iris Board unanimously recommends voting FOR the Business Combination Proposal and other proposals.

Sentiment

Score: 6

Explanation: The document is largely factual, but the numerous risks and uncertainties associated with the business combination and Liminatuss operations temper the overall sentiment.

Positives

• The Iris Board believes that Liminatus has an experienced management team with a proven track record of collaboration with pharmaceutical companies, research institutions, and academic centers.
• The Iris Board believes that Liminatus is well-positioned to be a public company, specifically with respect to its size and the scalability of its technology.
• The PIPE Equity Investment will provide $25,000,000 in new financing for the combined company.

Negatives

• If the Business Combination Proposal is not approved, Iris will not consummate the Business Combination and will be required to dissolve and liquidate.
• The trading market for ParentCo Common Stock may be less liquid than the market for shares of Iris common stock was prior to consummation of the Business Combination.
• ParentCo may not be able to meet the listing standards for Nasdaq or another national securities exchange.
• With less funds available from the Trust Account, the working capital infusion from the Trust Account into ParentCos business will be reduced.

Risks

• The success of Liminatus depends on the success of the Liminatus assets, and its anticipated clinical trials of the Liminatus assets may not be successful.
• Liminatus will need substantial additional funds to advance development of product candidates and its GCC cancer vaccine, and it cannot guarantee that it will have sufficient funds available in the future to develop and commercialize its current or potential future product candidates and technologies.
• If Liminatus is unable to raise capital when needed, or on acceptable terms, it may be forced to delay, reduce and/or eliminate one or more of its development programs or future commercialization efforts.
• The Sponsor, Iriss directors and executive officers, and their affiliates, own interests in Iris that will be worthless if the transactions are not approved, which may have influenced their decisions.
• The terms of the Business Combination Agreement provide that Iris will not have any surviving remedies against Liminatus or its equityholders after the closing to recover for losses as a result of any inaccuracies or breaches of Liminatuss representations, warranties, or covenants set forth in the Business Combination Agreement.
• The potential that a significant number of Iriss stockholders elect to redeem their shares prior to the consummation of the Business Combination, which would reduce the amount of cash available following the closing.
• The risk that the Transactions might not be consummated or completed in a timely manner or that the closing might not occur despite Iriss best efforts, including by reason of a failure to obtain the approval of Iriss stockholders, litigation challenging the Business Combination or that an adverse judgment granting permanent injunctive relief could indefinitely enjoin the consummation of the Business Combination.

Future Outlook

ParentCo will apply to list its common stock and warrants on Nasdaq under the symbols LIMN and LIMNW, respectively. We expect the Iris Class A Common Stock, Iris Units and Iris warrants will be delisted from Nasdaq.

Management Comments

• The Iris Board unanimously recommends that our stockholders vote FOR the Business Combination Proposal and FOR the other proposals presented in this proxy statement/prospectus.

Industry Context

The global cancer therapy market was valued at $70 billion in 2022 and is expected to reach $120 billion in 2026, representing a CAGR of 14.3%.

Comparison to Industry Standards

• The document mentions that Liminatus is currently available at a discount compared to its peers (based upon the current enterprise values of comparable public companies with similar technologies).
• The document mentions that the global cancer therapy market was valued at $70 billion in 2022 and is expected to reach $120 billion in 2026, representing a CAGR of 14.3%.
• The document mentions that the CAR-T cell therapy market size is expected to reach $20.56 billion by 2029 (from $1.96 billion in 2021), representing a compound annual growth rate (CAGR) of 31.6% during the forecast period from 2022 to 2029.

Management Changes

Corporate Governance

Related Party Transactions

• The Sponsor holds Founder Shares and Private Placement Warrants.
• The Sponsor is entitled to reimbursement of out-of-pocket expenses.
• The Sponsor has made outstanding loans to Iris.
• The Sponsor has agreed to indemnify Iris to ensure that the proceeds in the Trust Account are not reduced below $10.00 per public share.
• The Sponsor and Iriss officers and directors will hold 6,900,000 shares of ParentCo Common Stock following the Business Combination.

Stakeholder Impact

• Public stockholders have the opportunity to redeem their shares for cash.
• The Business Combination may be consummated even though the funds available from the Trust Account and the number of public stockholders are reduced as a result of redemptions by public stockholders.
• The trading market for ParentCo Common Stock may be less liquid than the market for shares of Iris common stock was prior to consummation of the Business Combination.
• ParentCo may not be able to meet the listing standards for Nasdaq or another national securities exchange.
• With less funds available from the Trust Account, the working capital infusion from the Trust Account into ParentCos business will be reduced.

Next Steps

• Stockholder vote on the Business Combination Proposal and other proposals at the Special Meeting on August 29, 2024.
• Consummation of the Business Combination, pending satisfaction of closing conditions.
• Application for listing of ParentCo Common Stock and warrants on Nasdaq under the symbols LIMN and LIMNW, respectively.

Key Dates

Keywords

Business Combination, Liminatus Pharma, Iris Acquisition Corp, Merger, Proxy Statement, Stockholders, ParentCo, SPAC, Redemption, Warrants